In the last week, the U.S. market has stayed flat, but over the past 12 months, it has risen by 30%, with earnings expected to grow by 16% per annum in the coming years. Amidst these conditions, identifying stocks with solid fundamentals and growth potential is crucial for investors looking to capitalize on market opportunities. Penny stocks may be an outdated term, but they still represent a valuable investment area; when backed by strong financials and balance sheet strength, these smaller or newer companies can offer significant upside potential without many of the associated risks.
Top 10 Penny Stocks In The United States
| Name |
Share Price |
Market Cap |
Financial Health Rating |
| WM Technology (MAPS) |
$0.3738 |
$65.58M |
★★★★★★ |
| LexinFintech Holdings (LX) |
$2.13 |
$360.08M |
★★★★★★ |
| Information Services Group (III) |
$3.11 |
$196.42M |
★★★★★★ |
| Golden Growers Cooperative (GGRO.U) |
$5.00 |
$77.45M |
★★★★★★ |
| Niagen Bioscience (NAGE) |
$4.96 |
$395.62M |
★★★★★★ |
| Cricut (CRCT) |
$4.43 |
$934.04M |
★★★★★★ |
| Village Farms International (VFF) |
$2.89 |
$326.9M |
★★★★★★ |
| SIGA Technologies (SIGA) |
$7.80 |
$327.41M |
★★★★★★ |
| BAB (BABB) |
$0.91 |
$6.57M |
★★★★★★ |
| Marine Petroleum Trust (MARP.S) |
$4.91 |
$9.9M |
★★★★★☆ |
Click here to see the full list of 346 stocks from our US Penny Stocks screener.
Let's dive into some prime choices out of the screener.
Pioneer Power Solutions
Simply Wall St Financial Health Rating:★★★★★★
Overview:Pioneer Power Solutions, Inc. designs, manufactures, integrates, refurbishes, distributes, sells, and services electric power systems and related equipment with a market cap of $35.40 million.
Operations:The company generates revenue from its Critical Power Solutions segment, which accounted for $27.63 million.
Market Cap:$35.4M
Pioneer Power Solutions, Inc. is navigating the volatile landscape of penny stocks with a market cap of US$35.40 million and recent revenue of US$27.63 million from its Critical Power Solutions segment. Despite being unprofitable, with a net loss of US$6 million in 2025, the company benefits from being debt-free and having short-term assets exceeding liabilities by a significant margin. Recent developments include securing contracts to provide electric vehicle charging solutions for school districts and utilities across the U.S., highlighting potential growth opportunities in clean energy infrastructure despite challenges such as delayed SEC filings impacting investor confidence.
Rapid Micro Biosystems
Simply Wall St Financial Health Rating:★★★★★★
Overview:Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in products for detecting microbial contamination in various manufacturing sectors, with a market cap of approximately $104.35 million.
Operations:The company generates revenue primarily from its Systems and Related LIMS Connection Software, Consumables, and Services segment, totaling $33.59 million.
Market Cap:$104.35M
Rapid Micro Biosystems, Inc. is navigating the penny stock market with a market cap of US$104.35 million and 2025 revenue of US$33.59 million, primarily from its Growth Direct platform used in pharmaceutical manufacturing. Despite being unprofitable and experiencing significant insider selling, the company maintains more cash than debt and short-term assets exceeding liabilities. Recent developments include a new multi-system order from Samsung Biologics, indicating potential growth in automation for microbial quality control. However, volatility remains high with a negative return on equity at -141.91%, and profitability is not expected within the next three years.
MariMed
Simply Wall St Financial Health Rating:★★★★☆☆
Overview:MariMed Inc. is involved in the cultivation, production, and sale of branded cannabis products in the United States, with a market cap of $31.51 million.
Operations:The company's revenue is derived from $159.83 million in activities related to the cultivation, processing, and sale of its branded cannabis products.
Market Cap:$31.51M
MariMed Inc., with a market cap of US$31.51 million, operates in the cannabis sector, generating US$159.83 million in revenue for 2025. Despite being unprofitable and having a high net debt to equity ratio of 98.7%, it trades at a discount compared to its estimated fair value and maintains sufficient cash runway for over three years due to positive free cash flow growth. Recent product expansions like the Berry In Love Betty chews highlight innovation within its branded offerings, potentially enhancing market presence despite ongoing financial challenges such as negative return on equity and uncovered long-term liabilities.
-
Click here to discover the nuances of MariMed with our detailed analytical financial health report.
-
Gain insights into MariMed's future direction by reviewing our growth report.
Seize The Opportunity
-
Navigate through the entire inventory of 346 US Penny Stocks here.
-
Interested In Other Possibilities? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PPSI RPID and MRMD.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
